Teva Pharmaceutical Industries (Teva) announced on 16 December 2012 that it had made an agreement with Handok Pharmaceuticals (Handok) to establish a business venture in South Korea.
Teva makes South Korean joint venture agreement
Home/Pharma News
|
Posted 11/01/2013
0
Post your comment

Under the terms of the agreement, the Israel-based generics giant will contribute its global resources, and be responsible for manufacturing and supplying a wide range of affordable and innovative medicines. South Korean Handok will be responsible for sales and marketing, distribution and regulatory affairs.
Teva will have a controlling stake in the new venture, gaining 51% of generated profits. The joint venture is expected to commence activities in the next few months, subject to receipt of applicable regulatory approvals. Financial details have not been disclosed.
The deal is Teva’s first in East Asian territory outside Japan and ‘is another significant step’ in Teva’s strategy to expand its presence in growing markets, according to Mr Itzhak Krinsky, Chairman of Teva Japan, Chairman of Teva South Korea and Head of Business Development Asia Pacific.
Mr Krinsky expects that Teva’s broad portfolio [including the multiple sclerosis blockbuster Copaxone (glatiramer acetate) and its branded generics], along with its R & D capabilities and its global infrastructure and know-how coupled with Handok’s expertise and strong reputation in South Korea, will enable the companies ‘to assume a prominent position in the Korean pharmaceutical market’.
Mr Young-Jin Kim, Handok’s Chief Executive Officer, said the venture is expected to ‘contribute greatly to the Korean pharmaceutical industry by supplying medicines at more affordable prices and providing innovative treatment solutions for central nervous system, respiratory and women’s health’.
The agreement will expand Teva’s presence in Asia and enable Teva to gain entrance to the Korean pharmaceutical market, valued at approximately US$14 billion.
Related articles
Teva cost-cutting and re-organization
Teva outlines expansion plans in Asia
Permission granted to reproduce for personal and educational use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Source: Handok, Teva
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment